The Russian manufacturers of the Sputnik V vaccine have filed a libel lawsuit in Brazil against the country's National Health Surveillance Agency (Anvisa) for “intentionally spreading false and inaccurate information” about the covid-19 inoculator after prohibiting its import, citing lack of data, the immunizer's Twitter account (@sputnikvaccine) reported.Add your comment!
Brazil's National Health Surveillance Agency (Anvisa) Monday recommended against the import of the Russian-made Sputnik V vaccine to fight the covid-19 pandemic, citing lack of proper documents required for approval as well as other health risks the antidote may imply.1 comment
Brazil's National Health Surveillance Agency (Anvisa) will evaluate this coming week the feasibility of importing the Russian-manufactured Sputnik V vaccine against covid-19.
While Argentina has already started trials to produce the Russian Sputnik V vaccine against covid-19, Brazil’s National Health Surveillance Agency (Anvisa) has filed a petition before the Federal Supreme Court (STF) for additional time to evaluate a registration request for the very same immunization shot.
Brazil's National Health Surveillance Agency (Anvisa) has given the green light to clinical trials on volunteers of a potential anti-Covid-19 vaccine produced by the Chinese laboratory Sichuan Clover Biopharmaceuticals, it was announced.
Brazil's National Health Surveillance Agency (Anvisa) will be sending a delegation to Russia next week to conduct an onsite review of the facilities where the Sputnik V vaccine is manufactured, it was announced Friday.
The risks to an expected economy recovery in Brazil during 2021 are increasing as delays in rolling out a vaccine program against coronavirus continues to be delayed, according to Moody's rating agency.
Brazil's health regulator Anvisa said over the weekend it had approved the import of 2 million doses of the COVID-19 vaccine developed by AstraZeneca and the University of Oxford, although the jab is not yet approved for use in the country.
Brazil’s health regulator Anvisa said China’s health authorities are not transparent in their authorization of COVID-19 vaccines for emergency use, a statement that may further inflame political tension in the country.
Brazil’s health regulator Anvisa said on Wednesday it was open to approving COVID-19 vaccines for emergency use and outlined the requirements for companies looking to do so.